Drug Safety

Portugal medicinal cannabis exports reached 66,305 kg in the first half of 2026, according to INFARMED, already 83% of the 79,883 kg shipped across all of 2025. The country’s medicines regulator published the figures in its mid-year report on the sector, which also shows cultivation and manufacturing licences easing back after several years of rapid expansion. Portugal began regulating medicinal cannabis in 2018, when the Assembly of the Republic approved a law covering marketing authorisations, prescribing and pharmacy dispensing. A […]

The European Medicines Agency’s Management Board met in Amsterdam on 10 and 11 June 2026. The European Commission reported that the first EU joint clinical assessment report appeared on 9 June 2026. Since the Health Technology Assessment Regulation took effect in January 2025, 18 JCAs have started. Seven Joint Scientific Consultations have finished under the Regulation, and the first JCAs for medical devices and in vitro diagnostics will begin in June 2026. Initiative Status Timing First EU joint clinical assessment […]

🔍 How does the FDA’s complete response letter change the game when it isolates manufacturing concerns? By focusing solely on production issues, the agency has clarified a potential approval pathway once these hurdles are addressed—offering new insights for drug developers. Discover the implications for regulatory strategy and timelines. #SyenzaNews #regulatoryaffairs #pharmaceuticals #innovation

What new medicines are set to reshape EU healthcare? In its July 2026 review, the CHMP endorsed several innovative treatments, expanding access to advanced therapies across Europe. Discover the full list and what it means for patients and industry. #SyenzaNews #pharmaceuticals #regulatoryaffairs #innovation #MarketAccess

Is dosing the new battleground in the tirzepatide vs semaglutide race? Comparative campaigns are facing scrutiny over how dosing differences are presented, influencing both clinical perceptions and market positioning. Read the full analysis to see what this means for future GLP-1 strategies. #SyenzaNews #pharmaceuticals #drugdevelopment #innovation #MarketAccess

🔍 How did the pandemic expose critical weaknesses in Brazil’s pharmaceutical supply chain? From raw-material dependencies to distribution bottlenecks, COVID-19 disruptions laid bare vulnerabilities that continue to threaten medicine availability and market access across the region. Read the full analysis to see what these lessons mean for building more resilient supply systems. #SyenzaNews #pharmaceuticals #globalhealth #MarketAccess #healthcarepolicy

Are regulatory gaps turning Portugal’s medicinal cannabis market into a playground for exploitation? ⚠️ This piece exposes how inconsistent licensing, weak oversight, and commercial pressure are compromising patient access and market integrity, and outlines practical governance fixes for policymakers and industry. Read the full article to see the risks mapped and the reforms that could restore transparency and trust. #SyenzaNews #regulatoryaffairs #pharmaceuticals #governance #healthcarepolicy

Can Colorado's plan to import prescription drugs cut costs without compromising safety? 💊🔍 This analysis breaks down Colorado’s FDA importation application—evaluating legal pathways, supply‑chain and quality safeguards, projected savings, and practical hurdles for state‑level implementation. It highlights what policymakers, payers, and manufacturers should watch next. Read the full article to see whether importation is a viable, scalable option for lowering drug prices. #SyenzaNews #pharmaceuticals #regulatoryaffairs #MarketAccess #healthcarepolicy

Who is accountable when an AI-driven clinical decision causes harm? 🤖⚖️ This article breaks down legal liability, ethical responsibilities, and practical governance for AI in clinical practice, highlighting where responsibility lies between clinicians, vendors, and health systems and how robust oversight can protect patients. Read the full piece to learn concrete steps for hospitals, regulators, and clinicians to manage AI risk and ensure safe, accountable deployment. #SyenzaNews #AIinHealthcare #HealthTech #healthcarepolicy #governance

Can gene therapy restore sight — and still fit into healthcare budgets? 👁️ This piece unpacks reimbursement pathways for vision-restoring gene therapies (e.g., RPE65/Luxturna), highlighting value assessment, long-term evidence needs, and practical payment models like outcomes-based agreements and annuities to manage uncertainty and budget impact. Read the full article to explore pragmatic strategies that payers, manufacturers, and clinicians can use to secure sustainable patient access. #SyenzaNews #biotechnology #HealthEconomics #MarketAccess #healthcarepolicy

🔬 Levacetylleucine Phase 3 results are out — what do they mean for patients and the future of treatment? This article breaks down the trial’s key findings, safety signals, and regulatory implications for levacetylleucine, highlighting what clinicians, payers, and investors should watch next. Read the full analysis to understand the endpoints, next steps toward approval, and the potential industry impact. #SyenzaNews #clinicaltrials #drugdevelopment #innovation #healthcarepolicy

Who’s watching mifepristone’s safety data—and why it matters? 🔬⚖️ A recent safety study reconfirms mifepristone’s established safety profile but highlights gaps in post‑market surveillance and regulatory transparency. These findings could influence oversight practices, prescribing guidance, and access for patients. Read the full article for a clear breakdown of the data, regulatory implications, and what stakeholders should watch next. #SyenzaNews #regulatoryaffairs #pharmaceuticals #healthcarepolicy #governance